/PRNewswire/ ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset.
REYKJAVIK, Iceland, Nov. 22, 2022 /PRNewswire/ ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset
Reykjavik-born drug discovery company 3Z completed a $2M funding round which will provide a boost for the startup to finalize its preclinical studies on
REYKJAVIK, Iceland, June 20, 2022 /PRNewswire/ 3Z, a Reykjavik based drug discovery company is pleased to announce the closure of a $2 million funding round led by seasoned investors in pharmaceuticals and medical technology. The just closed funding will accelerate finalization of preclinical studies on 3Z's lead therapeutic candidates in ADHD and insomnia. Using its unique zebrafish screening.